ivo's home

Data from the Greater Cincinnati and Northern Kentucky region show that stroke rates among adults aged 20 to 54 nearly doubled between 1993 and 2020, rising from 33.9 to 62.2 cases per 100,000 person-years. This increase was driven almost entirely by ischemic strokes, which occur when a blood vessel supplying the brain becomes blocked. While 30-day survival rates improved slightly during the same period, more younger people are now left to manage lasting neurological damage.

The study observed an increase in known risk factors like hypertension, diabetes, and substance use—particularly marijuana—among stroke patients over the decades. However, because researchers lacked a control group of healthy peers, the data cannot establish a direct causal link between these rising risk factors and the increase in strokes. It remains a troubling epidemiological shift without a definitive explanation.

more: https://www.sciencedaily.com/releases/2026/10/261014015459.htm

my other side: ivo.blogspot.com

Ice baths relieve next-day muscle soreness by dampening the body's acute inflammatory response. But researchers point out that this same inflammation is what signals muscles to adapt and grow stronger over the long term. Using cold plunges too frequently trades away permanent gains just to avoid temporary discomfort.

It is a useful reminder that healing and strengthening are often biologically opposed processes. If a hard workout is meant to build capacity rather than just finish a task, letting the inflammation run its course appears to be the more productive choice.

more: https://www.sciencedaily.com/releases/2026/10/261013015805.htm

my other side: ivo.blogspot.com

Researchers at Cedars-Sinai have found that senescent cells use the protein PD-L2 to evade immune clearance. When scientists blocked or removed PD-L2 in mice, the animals showed reduced accumulation of these aging cells, lower inflammation, and improvements in grip strength and blood sugar processing.

The mechanism points to a concrete target for clearing out lingering cells that drive age-related decline. Still, moving from mouse models to human therapy is a long path, and we do not yet know if blocking PD-L2 is safe or effective in people.

more: https://www.sciencedaily.com/releases/2026/10/261013015800.htm

my other side: ivo.blogspot.com